Person:
Mas Zubiri, Alicia

Profile Picture
First Name
Alicia
Last Name
Mas Zubiri
URI
https://hdl.handle.net/20.500.14352/84522
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Veterinaria
Department
Sanidad Animal
Area
Identifiers
UCM identifierScopus Author IDDialnet ID

Filters

20191
Reset filters

Settings

End date: 2019 × Subject: 636.09:615.37 ×

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Strength and medium-term impact of HisAK70 immunization in dogs: Vaccine safety and biomarkers of effectiveness for ex vivo Leishmania infantum infection
    (Comparative Immunology, Microbiology and Infectious Diseases, 2019) Martínez Rodrigo, Abel; Mas Zubiri, Alicia; Fernández-Cotrina, Javier; Belinchón-Lorenzo, Silvia; Orden Gutiérrez, José Antonio; Arias, Pablo; Fuente López, Ricardo De La; Carrión Herrero, Francisco Javier; Domínguez Bernal, Gustavo Ramón
    HisAK70 candidates have successfully been tested in cutaneous (CL) and visceral leishmaniosis (VL) mouse models. Here, we analyse different biomarkers in dog trials after a heterologous immunization strategy with a HisAK70 candidate (plasmid DNA plus adoptive transfer of peripheral blood-derived dendritic cells (DCs) pulsed with the same pathoantigen and CpG ODN as an adjuvant) to explore the antileishmanial activity in an ex vivo canine co-culture system in the presence of Leishmania infantum parasites. In the canine model, the heterologous HisAK70 vaccine could decrease the infection index in the DC-T cell co-culture system by up to 54% after 30 days and reach almost 67% after 100 days post-immunization, respectively, compared to those obtained in the control group of dogs. The observed security and potential to fight ex vivo L. infantum infection highlight a HisAK70 heterologous immunization strategy as a promising alternative to evaluate its effectiveness against canine VL.